Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients.

Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A.

Ann Surg Oncol. 2010 Dec;17(12):3252-8. doi: 10.1245/s10434-010-1160-7. Epub 2010 Jun 18.

2.

Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.

Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P.

Asian Pac J Cancer Prev. 2012;13(2):459-62.

3.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840
4.

Presenting features of breast cancer differ by molecular subtype.

Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M.

Ann Surg Oncol. 2009 Oct;16(10):2705-10. doi: 10.1245/s10434-009-0606-2. Epub 2009 Jul 11.

PMID:
19593632
5.

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M; South and South-East Swedish Breast Cancer Groups.

Acta Oncol. 2017 Jan;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. Epub 2016 Oct 20.

PMID:
27762648
6.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26.

PMID:
19034706
7.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
8.

Invasive lobular carcinoma predicts micrometastasis in breast cancer.

Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A.

J Surg Res. 2012 Sep;177(1):93-6. doi: 10.1016/j.jss.2012.03.014. Epub 2012 Mar 28.

9.

Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.

Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.

Oncology. 2012;83(4):228-33. doi: 10.1159/000341537. Epub 2012 Aug 16.

PMID:
22907070
10.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

11.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
12.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
13.

Unexpected features of breast cancer subtype.

Liu YH, Wang OC, Chen ED, Cai YF, Pan CM, Yang F, Zhang XH.

World J Surg Oncol. 2015 Aug 15;13:249. doi: 10.1186/s12957-015-0665-8.

14.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.

PMID:
21442348
15.

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

Hum Pathol. 2008 Dec;39(12):1809-15. doi: 10.1016/j.humpath.2008.05.010. Epub 2008 Aug 19.

PMID:
18715613
16.

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen.

BMC Cancer. 2011 Jun 21;11:262. doi: 10.1186/1471-2407-11-262.

17.

Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K.

J BUON. 2013 Jul-Sep;18(3):608-13.

PMID:
24065471
18.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
19.

[Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].

Wu SY, Tan Y, Guan YS.

Zhonghua Gan Zang Bing Za Zhi. 2016 Jun;24(6):422-8. doi: 10.3760/cma.j.issn.1007-3418.2016.06.006. Chinese.

PMID:
27465945
20.

Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?

Truong PT, Sadek BT, Lesperance MF, Alexander CS, Shenouda M, Raad RA, Taghian AG.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):57-64. doi: 10.1016/j.ijrobp.2013.09.024. Epub 2013 Oct 22.

PMID:
24161421

Supplemental Content

Support Center